Literature DB >> 18479639

Phase 2 study of silver leaf dressing for treatment of radiation-induced dermatitis in patients receiving radiotherapy to the head and neck.

Peter Vavassis1, Michel Gelinas, Jean Chabot Tr, Phuc Felix Nguyen-Tân.   

Abstract

OBJECTIVE: The use of silver leaf dressing is common in the treatment of burn victims owing to its capacity to improve healing and inherent antimicrobial properties. The goal of this study was to investigate its effectiveness in the treatment of radiation-induced dermatitis in a patient population receiving radiotherapy with or without concurrent chemotherapy for various carcinomas of the head and neck compared with our current standard of care, silver sulfadiazine (Flamazine).
METHODS: Twelve patients presenting with cancers of the head and neck region with Radiation Therapy Oncology Group (RTOG) grade 2 or more skin toxicity were offered topical treatment of silver sulfadiazine and silver leaf dressing. Each patient applied silver-leaf dressing on one side of the neck and silver sulfadiazine on the other. Three independent observers evaluated the patients based on standardized digital photography and regular follow-up by the treating physician. The sign test was used to evaluate whether the observed difference was statistically significant.
RESULTS: There was no improvement in RTOG grade skin toxicity. However, within the same grade, two of three observers agreed on some degree of improvement in the dermatitis with silver leaf dressing compared with silver sulfadiazine. As well, 67% of patients reported improved pain control on the side treated with silver leaf dressing. Sign test analysis indicated that the use of silver-leaf dressing gave significantly superior results when compared with silver sulfadiazine (p = .035).
CONCLUSION: Silver leaf dressing does not appear to be superior to our standard treatment for radiation-induced dermatitis when the RTOG grading system is used. It does, however, seem to reduce the severity of reaction within the same grade, accelerate healing, and provide improved pain control over standard treatment. It shows promise regarding symptom control and merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479639

Source DB:  PubMed          Journal:  J Otolaryngol Head Neck Surg        ISSN: 1916-0208


  6 in total

1.  Topical silver sulfadiazine for the prevention of acute dermatitis during irradiation for breast cancer.

Authors:  Simin Hemati; Omid Asnaashari; Mostafa Sarvizadeh; Behnam Nasiri Motlagh; Mojtaba Akbari; Mina Tajvidi; Abbas Gookizadeh
Journal:  Support Care Cancer       Date:  2011-10-19       Impact factor: 3.603

2.  Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: a pilot study.

Authors:  Isabella Uzaraga; Bev Gerbis; Eleanor Holwerda; Dan Gillis; Elaine Wai
Journal:  Support Care Cancer       Date:  2011-08-17       Impact factor: 3.603

3.  Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature.

Authors:  N Salvo; E Barnes; J van Draanen; E Stacey; G Mitera; D Breen; A Giotis; G Czarnota; J Pang; C De Angelis
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

Review 4.  Modern Dressings in Prevention and Therapy of Acute and Chronic Radiation Dermatitis-A Literature Review.

Authors:  Konrad Zasadziński; Mateusz Jacek Spałek; Piotr Rutkowski
Journal:  Pharmaceutics       Date:  2022-06-06       Impact factor: 6.525

5.  Recove® burn ointment for managing acute radiodermatitis in patients with breast cancer: A double blind randomized controlled trial.

Authors:  Nargeuss Abbaszade Marzbali; Ebrahim Zabihi; Alexis Vallard; Nicolas Magne; Mohammad Moslemi; Dariush Moslemi
Journal:  Caspian J Intern Med       Date:  2022

6.  Twelve-Month Evaluation of Temperature Effects of Radiotherapy in Patients after Mastectomy.

Authors:  Agnieszka Baic; Dominika Plaza; Barbara Lange; Łukasz Michalecki; Agata Stanek; Krzysztof Ślosarek; Armand Cholewka
Journal:  Int J Environ Res Public Health       Date:  2022-02-28       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.